143.67
5.75 (4.17%)
| Previous Close | 137.92 |
| Open | 139.56 |
| Volume | 837,913 |
| Avg. Volume (3M) | 364,795 |
| Market Cap | 4,151,876,096 |
| Price / Earnings (TTM) | 34.45 |
| Price / Earnings (Forward) | 18.62 |
| Price / Sales | 12.36 |
| Price / Book | 4.05 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 37.17% |
| Operating Margin (TTM) | 41.03% |
| Diluted EPS (TTM) | 4.17 |
| Quarterly Revenue Growth (YOY) | 94.90% |
| Quarterly Earnings Growth (YOY) | 3,734.00% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 9.65 |
| Operating Cash Flow (TTM) | 138.50 M |
| Levered Free Cash Flow (TTM) | 76.74 M |
| Return on Assets (TTM) | 8.66% |
| Return on Equity (TTM) | 13.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Krystal Biotech, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 3.88 |
|
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.21% |
| % Held by Institutions | 104.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 240.00 (HC Wainwright & Co., 67.05%) | Buy |
| Median | 204.00 (41.99%) | |
| Low | 155.00 (Citigroup, 7.89%) | Hold |
| Average | 200.75 (39.73%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 136.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Jun 2025 | 240.00 (67.05%) | Buy | 143.67 |
| 06 May 2025 | 240.00 (67.05%) | Buy | 139.47 | |
| Citigroup | 16 May 2025 | 155.00 (7.89%) | Hold | 130.60 |
| Chardan Capital | 07 May 2025 | 219.00 (52.43%) | Buy | 136.80 |
| Guggenheim | 07 May 2025 | 189.00 (31.55%) | Buy | 136.80 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jun 2025 | Announcement | Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa |
| 03 Jun 2025 | Announcement | Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference |
| 07 May 2025 | Announcement | Krystal Biotech to Present at BofA Securities 2025 Health Care Conference |
| 06 May 2025 | Announcement | Krystal Biotech Announces First Quarter 2025 Financial and Operating Results |
| 28 Apr 2025 | Announcement | Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa |
| 24 Apr 2025 | Announcement | Krystal Biotech to Present at Upcoming Scientific Conferences |
| 17 Apr 2025 | Announcement | Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 |
| 07 Apr 2025 | Announcement | Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |